Immunosynthen is our novel immunostimulatory ADC platform designed to take ADCs beyond traditional cytotoxic drugs to targeted stimulation of the innate immune system. Through the safe and efficient delivery of a novel immunomodulatory STING agonist, ADCs created with our Immunosynthen platform have the potential to address the challenges of efficacy, delivery and tolerability.
Stimulator of Interferon Genes (STING) is a well-studied innate immune pathway capable of inducing anti-tumor immune activity. Our preclinical data show that the anti-tumor activity of Immunosynthen STING-agonist ADCs involves the targeted activation of the STING pathway in both tumor-resident immune cells and in tumor cells, in an antigen binding-dependent manner. This one-two punch provides the potential for enhanced anti-tumor activity with a STING-agonist ADC when compared to other innate immune approaches that activate only the immune cells. Further, we have generated preclinical data across multiple targets and tumor models showing complete regression of tumors in vivo after a single low, well-tolerated dose, consistent with increased cytokine expression and immune cell infiltration within the tumor and immune memory. In addition, we have demonstrated the tolerability and excellent pharmacokinetic profile of Immunosynthen ADCs in non-human primates, after multiple IV doses and at exposures significantly higher than those required for robust efficacy in mice.
To learn more, see our Immunosynthen STING-Agonist ADC Platform and Pipeline webinar
We are building a deep pipeline of Immunosynthen ADCs with a broad range of clinical indications and deep potential for value-creating partnerships. Our first Immunosynthen ADC development candidate, XMT-2056, is in IND-enabling studies and is expected to enter a Phase I dose escalation clinical study in early 2022.